Novartis’ rival gets rejected, AstraZeneca’s deal collapses and a new myeloma drug clears the FDA.
August 19, 2026

1. Clinicians flag safety concerns for Prader-Willi drug after 7 deaths Full story

2. FDA rejects cancer therapy positioned to rival Novartis treatment Full story

3. Even the best-run spine ORs see preventable positioning injuries. Learn why in this webinar.

 

4. How AstraZeneca’s $400B Bristol Myers deal fell apart Full story

5. mRNA-based melanoma vaccine succeeds in phase 3 trial Full story

6. Isolated marketing tactics are failing orthopedic groups. See the integrated fix by registering for this webinar.

 

7. FDA approves new class of multiple myeloma drug Full story

8. 8 GLP-1 updates to know Full story

Becker’s Learning Opportunities

9. AI agents raise a new identity question: who — or what — is requesting PHI? Get answers here.

10. See how Baptist Health built a contract-intelligent supply chain — here.

11. Case managers spend days on hard-to-place discharges. A faster way here.

12. Becker’s August webinar lineup: CDI, remote monitoring, revenue cycle AI and staff safety. See the sessions here.

 

 

Apply to attend complimentary as a guest reviewer here! Opportunity exclusive to those directly employed by a provider organization.

 
 

 

Contact Us, Feedback, or Questions – Email ldyrda@beckershealthcare.com

Manage Preferences     Unsubscribe     Forward to a friend    Contact Us     

Privacy Policy     

 

View our profile on LinkedIn Follow us on Twitter Follow us on Facebook Check out our YouTube Channel    

17 N. State, Suite 1800 | Chicago, IL 60602
Becker’s Hospital Review, A Becker’s Healthcare Publication